Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-14 of 14
Keywords: Dupilumab
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Jeivicaa Thevan, Eloi Schmauch, Jakob Nilsson, Carole Florence Guillet, Andrea Boesch, Lukas Krähenbühl, Barbara Meier-Schiesser, Peter Schmid-Grendelmeier, Thomas Kündig, Antonios G.A. Kolios
Journal:
Dermatology
Dermatology 1–8.
Published Online: 29 July 2024
...Jeivicaa Thevan; Eloi Schmauch; Jakob Nilsson; Carole Florence Guillet; Andrea Boesch; Lukas Krähenbühl; Barbara Meier-Schiesser; Peter Schmid-Grendelmeier; Thomas Kündig; Antonios G.A. Kolios Introduction: Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid...
Journal Articles
Journal:
Dermatology
Dermatology (2024) 240 (4): 589–596.
Published Online: 24 May 2024
...Yu-Qing Hu; Jian-Zhong Zhang; Yan Zhao Introduction: With the aging of the population in China, the prevalence of atopic dermatitis (AD) is high in elderly patients. These patients usually have more comorbidities and they need more effective and safer treatments. Dupilumab is an anti-interleukin-4...
Journal Articles
Emilio Berna-Rico, Esther Fiz-Benito, Jose Manuel Busto-Leis, Guillermo Servera-Negre, Raul de Lucas-Laguna, Marta Feito-Rodriguez
Journal:
Dermatology
Dermatology (2024) 240 (2): 337–342.
Published Online: 30 November 2023
...Emilio Berna-Rico; Esther Fiz-Benito; Jose Manuel Busto-Leis; Guillermo Servera-Negre; Raul de Lucas-Laguna; Marta Feito-Rodriguez Introduction: Dupilumab has recently been shown to be effective in children under 6 years of age with atopic dermatitis (AD). Nevertheless, real-life and long-term...
Journal Articles
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates)
,
Karger e-Journal Backfile Collection 2023
,
Dermatology
,
Immunology and Allergy
Journal:
Dermatology
Dermatology (2023) 239 (4): 646–657.
Published Online: 08 August 2023
...Zheng Su; Yue-Ping Zeng Background: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent...
Journal Articles
Journal:
Dermatology
Dermatology (2023) 239 (4): 658–663.
Published Online: 08 August 2023
... was to evaluate the efficacy and safety of dupilumab in the treatment of PN in adults. Method: This study is a retrospective cohort study. Twenty-four adult patients with PN were included and treated with dupilumab. The primary outcomes were the mean reduction in the Investigator’s Global Assessment (IGA) score...
Journal Articles
Clara Richter, Jürg Hafner, Manuel Schuermann, Matteo Tanadini, Nisia Trisconi, Peter Schmid-Grendelmeier, Thomas Kündig, Mirjam Nägeli, Marie-Charlotte Brüggen, Carole Guillet
Journal:
Dermatology
Dermatology (2023) 239 (5): 811–817.
Published Online: 27 June 2023
.... It reduces patients’ quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through blockade of the IL-4 receptor. Patients with CPG who receive dupilumab often report great improvement in itch and overall...
Journal Articles
Aviël Ragamin, Anouk E.M. Nouwen, Virgil A.S.H. Dalm, Minke M.F. van Mierlo, Carsten R. Lincke, Suzanne G.M.A. Pasmans
Journal:
Dermatology
Dermatology (2023) 239 (1): 72–80.
Published Online: 24 January 2023
... for patients with NS and current therapy is mostly supportive. The effects of intravenous immunoglobulins (IVIGs), ixekizumab, and dupilumab have scarcely been reported. Additionally, the role of anakinra in patients with NS has never been investigated. Objectives: The objective was to report our experiences...
Journal Articles
Journal:
Dermatology
Dermatology (2022) 238 (6): 1073–1075.
Published Online: 17 November 2022
...Dan Slodownik; Assi Levi; Moshe Lapidoth; Shlomo Moshe Background: Occupational contact dermatitis may progress to a chronic course with an unfavorable prognosis. Dupilumab has been shown to be effective as a treatment for moderate-to-severe atopic dermatitis as well as other types of dermatitis...
Journal Articles
Journal:
Dermatology
Dermatology (2022) 238 (6): 1060–1072.
Published Online: 13 June 2022
...Ya-Chu Shih; Marvin Chia-Han Yeh; Fu-An Yang; Hung-Chou Chen Background: Dupilumab ameliorates the signs and symptoms of atopic dermatitis (AD) and improves the patient’s quality of life. Multiple-dose regimens of dupilumab have been applied by clinicians, but the efficacy of some regimens remains...
Journal Articles
Andrea Chiricozzi, Niccolò Gori, Lucia Di Nardo, Flaminia Antonelli, Cristiano Caruso, Giacomo Caldarola, Laura Calabrese, Cristina Guerriero, Clara De Simone, Ketty Peris
Journal:
Dermatology
Dermatology (2022) 238 (4): 717–724.
Published Online: 28 October 2021
... as a negative factor impacting on dupilumab response, although a comparison of exposed versus unexposed areas is not currently available. Objectives: The aim of this study is to evaluate the clinical response to dupilumab depending on the presence or persistency of AD skin manifestations in specific body areas...
Journal Articles
Niccolò Gori, Andrea Chiricozzi, Dalma Malvaso, Dario Francesco D’Urso, Giacomo Caldarola, Clara De Simone, Ketty Peris
Journal:
Dermatology
Dermatology (2021) 237 (4): 535–541.
Published Online: 21 January 2021
...Niccolò Gori; Andrea Chiricozzi; Dalma Malvaso; Dario Francesco D’Urso; Giacomo Caldarola; Clara De Simone; Ketty Peris Background: Dupilumab, a monoclonal antibody inhibiting the signaling pathway of IL-4/IL-13, was shown to be safe and effective in the treatment of moderate/severe atopic...
Journal Articles
Mariateresa Rossi, Chiara Rovati, Mariachiara Arisi, Cesare Tomasi, Irene Calzavara-Pinton, Marina Venturini, Piergiacomo Calzavara-Pinton
Journal:
Dermatology
Dermatology (2021) 237 (3): 407–415.
Published Online: 05 January 2021
...Mariateresa Rossi; Chiara Rovati; Mariachiara Arisi; Cesare Tomasi; Irene Calzavara-Pinton; Marina Venturini; Piergiacomo Calzavara-Pinton Background: Since the best clinical response to dupilumab is achieved after 12–16 weeks, a combination therapy at the beginning of the treatment could...
Journal Articles
Journal:
Dermatology
Dermatology (2019) 235 (3): 187–188.
Published Online: 06 February 2019
.... Dupilumab Atopic dermatitis Hand dermatitis Letter Received: December 17, 2018 Accepted: December 27, 2018 Published online: February 6, 2019 Dermatology 2019;235:187 188 DOI: 10.1159/000496481 A Retrospective Review of Dupilumab for Hand Dermatitis Nicole Lee a Naina Chipalkatti a Pedro Zancanaro b...
Journal Articles
Journal:
Dermatology
Dermatology (2018) 233 (5): 344–357.
Published Online: 11 January 2018
..., 2017. We excluded therapies that could be categorized as either traditional Chinese medicine, herbal medicine, probiotics, histamine/leukotriene blockers, immuno-adsorption, or immunostimulants. The humanized monoclonal antibody (mAb) dupilumab binds to the α-subunit of the IL-4 receptor, which...